BrainStorm Cell Therapeutics Inc. Receives Notice Of Allowance To Grant European Patent Covering Its Stem Cells For The Treatment Of CNS Diseases
1/8/2014 9:51:05 AM
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received notification from the European Patent Office (EPO) of its intention to grant the company’s patent application No. EP06766101.7 entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases."
Help employers find you! Check out all the jobs and post your resume.
comments powered by